Arteriolar disease of the brain manifests itself structurally as lacunar infarcts and leukoaraiosis, and may also lead to cognitive dysfunction. Although the pathogenesis of leukoaraiosis is somewhat controversial, its strong association with vascular risk factors, in particular hypertension, implies a microvascular etiology. These subclinical brain changes and their associated effects on cognition are likely to be associated with microvascular disease in other organs. In the article by Haan et al. 1 in this issue of Neurology ® , the association between retinal microvascular changes and cerebral outcomes (i.e., cognitive performance and subclinical brain lesions and volume) is evaluated in the Women's Health Initiative (WHI).
In this WHI study, although retinopathy is found infrequently (in 7.6% of 511 participants), it is associated with worsening over 10 years on cognitive assessment with the modified Mini-Mental State Examination (3MSE) and with larger ischemic volumes on brain MRI (using a composite measure of lacunar infarcts and white matter hyperintensities [WMH] ). This parallels other epidemiologic studies that have demonstrated associations between retinal microvascular disease and MRI evidence of small vessel disease (lacunar infarcts or WMH) 2 and between retinopathy and cognitive decline. 3 The use, however, of a measure combining lacunar infarcts and WMH into one composite variable is novel.
Consistent with the findings from neuroimaging studies, macroinfarcts, such as the cystic and lacunar infarcts that are visible in gross brain autopsy examination, are associated with dementia and cognitive impairments. 4 However, recent studies have shown microinfarcts (focal lesions attributed to ischemia), which are invisible to the naked eye and only detectable microscopically, may play a more important role in cognitive impairment and dementia. 4 -6 These microinfarcts often occur concomitantly with macroinfarcts 5, 6 and are associated with elevated blood pressure 7 and diabetes. 8 The presence of a high number of microinfarcts has been independently associated with dementia and with impairments in perceptual speed and semantic and episodic memory. 6 When microinfarcts are taken into account, the association between macroinfarcts and dementia has diminished to null. 5 The study by Haan et al. adds to the growing evidence of a causal association of small vessel disease and cognition, but most importantly, it further validates retinopathy as an early marker for brain small vessel disease in living persons.
Because of the shared microvascular mechanism behind retinopathy and subclinical lacunes and white matter disease, this association is biologically plausible and has been supported by other studies. In addition, cognitive dysfunction in older adults is usually due to vascular disease, degeneration, or a combination of both. These WHI data support a vascular etiology or at least a vascular contribution to cognitive impairment. Because retinopathy is relatively infrequent in this cohort, however, it is only evaluated as a single dichotomized variable, which limits the ability to evaluate lesser degrees of retinopathy, or different types of retinopathy, in comparison to more advanced retinal microvascular disease.
It is difficult to interpret the temporal relationship between retinopathy or ischemic changes on the MRI and cognitive performance in this study, because the baseline cognitive assessment used in the analysis occurred 3.8 years, on average, before the retinal evaluation and 8 years before the brain MRI. As the authors point out, there was a decline in cognitive performance before retinopathy was evaluated. It is certainly possible that those individuals with retinopathy would have been identified as having retinopathy had they been evaluated sooner, but the strongest clinical utility of retinopathy evaluation would be if it clearly identified individuals before they developed cognitive decline. Treatments for dementing illnesses, when they become available, are most likely to be of benefit in individuals in the preclinical stage of the disease, and markers that identify those at risk for subsequent cognitive decline are most critical. Although this emphasis on preclinical biomarkers is primarily a concern for neurodegenerative dementias such as Alzheimer disease, it is also relevant for cerebrovascular disease. Prevention is most likely to be effective if an elevated risk were identified early in the development of cerebral microvascular disease. In addition, there is evidence that not only does vascular disease contribute to dementia in individuals who also have Alzheimer-type changes, but that vascular risk factors 9 and vascular disease might actually worsen Alzheimer neuropathology itself. Thus, identifying targets for early intervention, even if they are vascular in mechanism, may be important in development of all dementing illnesses.
This study highlights the potential importance of retinal evaluation in understanding the extent of cerebral microvascular disease that may be present in older adults. Retinopathy was significantly associated with cognitive scores and cerebral microvascular disease independent of the effect of hypertension and diabetes-this suggests either that it captures information beyond a simple binary yes/no diagnosis of hypertension and diabetes, or that perhaps preclinical disease is better captured with measures of retinopathy (hypertension and diabetes were both classified as present or absent at baseline in this WHI evaluation). These data also provide further support for a microvascular etiology for cognitive decline. A retinal evaluation may be a way to screen for an underlying vascular etiology in individuals with evidence of cognitive impairment or dementia. More aggressive management of vascular risk factors might be indicated. Further studies that evaluate the role of retinal screening in individuals at risk for cognitive impairment or dementia and the impact of this screening on subsequent cognitive decline are needed.
